Bayer's sevabertinib just became the third FDA-approved HER2-directed therapy for lung cancer, posting a 71% response rate in a patient population that barely had options a few years ago. The HER2 lung cancer market is suddenly a three-way race, and the competition is heating up fast.
A Rare Mutation Gets a New Weapon
For years, if you had a HER2 mutation driving your lung cancer, your options were painfully thin. HER2 is famous as a breast cancer target, but it also shows up in a small slice of lung cancers: roughly 1% to 4% of all non-small cell lung cancer (NSCLC) cases. That's a small percentage, but NSCLC is the most common cancer killer on the planet. Even a few percent translates to thousands of patients every year who've been stuck with limited targeted options.
Now Bayer is muscling into that space. On November 19, 2025, the FDA granted accelerated approval to sevabertinib, branded as Hyrnuo, for adults with locally advanced or metastatic HER2-mutant non-squamous NSCLC who've already tried at least one prior treatment. It's an oral pill, it's targeted, and it works surprisingly well.
What Sevabertinib Actually Does
Think of HER2 mutations like a stuck gas pedal inside a cancer cell. The mutation jams the growth signal into the "on" position, telling the tumor to keep growing no matter what. Sevabertinib is a reversible tyrosine kinase inhibitor (TKI), which is a fancy way of saying it's a pill that blocks that jammed signal at the source.
What makes it interesting is its design origin. Bayer developed this molecule through a collaboration with the Broad Institute, and it was one of the first reversible small-molecule inhibitors to target both HER2 activating mutations and mutant EGFR (a related growth receptor) in clinical testing. Unlike antibody-based therapies that need to be infused at a clinic, sevabertinib is oral. Patients take it at home. That convenience factor matters more than people realize when you're talking about a cancer population that often has advanced disease.
The FDA also cleared the Oncomine Dx Target Test as a companion diagnostic alongside the approval. Doctors need a confirmed HER2 (ERBB2) tyrosine kinase domain activating mutation before prescribing. No mutation, no prescription.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The approval was based on the SOHO-01 trial, and the results were strong enough to earn accelerated approval (which the FDA reserves for drugs that fill serious unmet needs, based on early evidence that's likely to predict real clinical benefit).
In patients who hadn't previously received a HER2-targeted therapy, the confirmed response rate was 71%. That means roughly seven out of ten patients saw their tumors shrink meaningfully. The median duration of those responses clocked in at 9.2 months, with 54% of responders still going strong at six months.
But Bayer also tested sevabertinib in a trickier group: patients who had already failed a HER2-directed antibody-drug conjugate (ADC). Even in that harder-to-treat population, the response rate was 38%. Getting a 38% response in patients whose cancer has already outsmarted one HER2 therapy is genuinely noteworthy. It suggests sevabertinib works through a different enough mechanism to catch tumors that have dodged other attacks.
A Three-Way Race for a Tiny Market
Here's where it gets competitive. Sevabertinib isn't arriving into an empty field; it's the third player in a rapidly crowding HER2-mutant NSCLC market.
Trastuzumab deruxtecan (T-DXd, sold as Enhertu) got there first, earning FDA approval for this population back in 2022. It's an antibody-drug conjugate, essentially a guided missile that delivers chemotherapy directly to HER2-expressing cells. In 2024, it expanded further with a tumor-agnostic approval for any solid tumor that's HER2 IHC 3+, giving it the broadest eligibility of the bunch.
Then came zongertinib (Hernexeos), another oral TKI that won accelerated approval in August 2025 for the same HER2-mutant NSCLC niche.
Now sevabertinib makes it a three-horse race. The market splits into two camps: T-DXd owns the broader territory (it can treat patients based on HER2 protein expression, not just mutations), while zongertinib and sevabertinib compete head-to-head in the narrower, mutation-defined lane. Both are oral pills targeting the same biomarker in the same patient population. The differentiation will come down to efficacy data, side effect profiles, and which drug oncologists feel most comfortable prescribing.
Why Bayer Is Playing the Long Game
The current approval is limited to second-line and beyond, meaning patients must have tried another treatment first. That keeps the addressable market relatively small. But Bayer clearly has bigger ambitions.
Sevabertinib has already received Breakthrough Therapy Designation in both the U.S. and China for first-line use in HER2-mutant NSCLC, supported by a separate cohort (Cohort F) of the ongoing SOHO-01 study. If Bayer can convert that into a first-line approval, the commercial picture changes dramatically. Instead of catching patients after they've failed chemotherapy or immunotherapy, sevabertinib would become the opening move.
Bayer is also running the panSOHO study, testing sevabertinib across multiple solid tumor types with HER2-activating mutations. That's the tumor-agnostic playbook: prove the drug works wherever the mutation appears, not just in lung cancer. It's a page straight out of the precision oncology handbook.
The Bigger Picture
This approval is one more brick in a wall that's been building for years. HER2-directed therapy used to be a breast cancer story, full stop. Now it's becoming a pan-cancer story, and NSCLC is the most active frontier.
For patients with HER2-mutant lung cancer, the shift has been remarkable. A few years ago, they had chemotherapy and a prayer. Now they have an ADC, two oral TKIs, and multiple clinical trials pushing into first-line and combination settings. The challenge has flipped: instead of having no targeted options, oncologists now face the (much better) problem of deciding which targeted option to use first.
Sevabertinib's 71% response rate in its target population is hard to ignore. Whether it can hold its own against zongertinib and T-DXd in real-world practice will depend on data that's still maturing, but Bayer has put a credible entry on the board. The HER2-mutant lung cancer market is tiny by oncology standards, but for the thousands of patients it affects each year, having three distinct treatment options instead of zero is the kind of progress that actually matters.
Clinical & Regulatory
4 min read
The Government Wants an AI Doctor for Your Heart
ARPA-H just bet $62.7 million that an AI can manage heart failure patients around the clock, prescribing drugs and ordering tests without waiting for a doctor. If it works, it could reshape how we treat the fastest-growing heart condition in America.
